SG Americas Securities
ABCL icon

SG Americas Securities’s AbCellera Biologics ABCL Stock Holding History

SG Americas Securities’s Portfolio ABCL Stock Details ABCL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-20,200
Closed -$70K – 3326
2026
Q1 		$70K Buy
+20,200
New +$72.7K ﹤0.01% 2989
2025
Q3 		– Sell
-21,979
Closed -$75K – 3349
2025
Q2 		$75K Buy
21,979
+6,402
+41% +$15.9K ﹤0.01% 2695
2025
Q1 		$35K Buy
+15,577
New +$44.7K ﹤0.01% 3310
2023
Q2 		– Sell
-36,208
Closed -$273K – 2213
2023
Q1 		$273K Buy
+36,208
New +$329K ﹤0.01% 2190
2022
Q4 		– Sell
-160,643
Closed -$1.59M – 3032
2022
Q3 		$1.59M Buy
160,643
+150,966
+1,560% +$1.66M 0.02% 709
2022
Q2 		$103K Buy
+9,677
New +$81.9K ﹤0.01% 3107

Other funds holding ABCL

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
TWC
TD Waterhouse Canada Toronto, Ontario, Canada $38B AUM 39.14% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
UBS AM
UBS AM Chicago, Illinois $550B AUM 43.33% 1-Year Est. Return
ACH
ArrowMark Colorado Holdings Denver, Colorado $2.4B AUM 42.85% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
Tudor Investment Corp
Tudor Investment Corp Stamford, Connecticut $71.9B AUM 42.37% 1-Year Est. Return

SG Americas Securities's ABCL Position: Q2 2026 in Review

SG Americas Securities sold out of AbCellera Biologics (ABCL) in Q2 2026, closing a stake of 20,200 shares — an estimated $70K sold.

SG Americas Securities first reported a position in ABCL in Q2 2022 and held it in 6 quarters. The position peaked at $1.59M in Q3 2022. 151 funds tracked by Wall St. Rank hold ABCL as of Q2 2026.

  • SG Americas Securities reported no remaining AbCellera Biologics position as of Q2 2026 after selling out during the quarter.
  • SG Americas Securities sold 20,200 AbCellera Biologics shares in Q2 2026, an estimated $70K.
  • SG Americas Securities first reported a position in AbCellera Biologics in Q2 2022 and held it in 6 quarters.
  • SG Americas Securities's AbCellera Biologics position peaked at $1.59M in Q3 2022.
  • 151 funds tracked by Wall St. Rank held AbCellera Biologics as of Q2 2026.

Based on SG Americas Securities's 13F filing for Q2 2026, filed 7 Aug 2026.